Sidebar: Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).
You may also be interested in...
FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product